1-4 of 4
Thomas Cerny
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Volker Diehl, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Andreas Engert
Journal: Blood
Blood (2008) 112 (11): 1558.
https://doi.org/10.1182/blood.V112.11.1558.1558
Published: 2008
Journal Articles

HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.

Andreas Engert, Jeremy Franklin, Rolf-Peter Mueller, Hans-Theodor Eich, Axel Gossmann, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony D. Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Beate Pfistner, Volker Diehl
Journal: Blood
Blood (2006) 108 (11): 99.
https://doi.org/10.1182/blood.V108.11.99.99
Published: 2006
Journal Articles

Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.

Michele Ghielmini, Kaspar Rufibach, Gilles Salles, Sergio Cogliatti, Leda Leoncini-Franscini, Claire Leger-Falandry, Martin Fey, Thomas Cerny, Giovanni Martinelli, Rolf Stahel, Andreas Lohri, Nicolas Ketterer, Martin Wernli
Journal: Blood
Blood (2004) 104 (11): 588.
https://doi.org/10.1182/blood.V104.11.588.588
Published: 2004
Journal Articles

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule

Clinical Trials & Observations
Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B. Cogliatti, Gabriella Pichert, Jörg Hummerjohann, Ursula Waltzer, Martin F. Fey, Daniel C. Betticher, Giovanni Martinelli, Fedro Peccatori, Urs Hess, Emanuele Zucca, Roger Stupp, Tibor Kovacsovics, Claudine Helg, Andreas Lohri, Mario Bargetzi, Daniel Vorobiof, Thomas Cerny, for the Swiss Group for Clinical Cancer Research (SAKK)
Journal: Blood
Blood (2004) 103 (12): 4416–4423.
https://doi.org/10.1182/blood-2003-10-3411
Published: 2004